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Healthcare Worker 
Acceptance of 
Pandemic (H1N1) 
2009 Vaccination, 
Morocco
To the Editor: In Morocco, the 
ﬁ  rst case of pandemic (H1N1) 2009 
was diagnosed on June 12, 2009 (1). 
Because a main determinant of public 
immunization success is healthcare 
workers’ support and recommenda-
tions and because little is known about 
such with regard to pandemic (H1N1) 
2009 vaccination in Morocco, our aim 
was to document healthcare workers’ 
knowledge, attitudes, practices, and 
acceptance of pandemic (H1N1) 2009 
vaccination in Morocco.
From January 15 through Febru-
ary 28, 2010, a structured, self-admin-
istered, anonymous questionnaire was 
distributed to a convenience sample of 
1,332 healthcare workers in 5 public 
hospitals in Rabat, Morocco. Com-
pleted questionnaires were analyzed 
by using SPSS version 10.0 (SPSS, 
Chicago, IL, USA).  The 1,002 re-
sponses gave a response rate of 75% 
(≈17% of the entire staff of the Uni-
versity Hospital of Rabat). 
We found that the hospital staff 
had acquired basic knowledge about 
transmission and prevention of the pan-
demic (H1N1) 2009 virus. Responses 
indicated that 218 (22%) study partic-
ipants had accepted vaccination (i.e., 
had been vaccinated) against this vi-
rus. Markedly more healthcare work-
ers in Morocco were undervaccinated 
than were those in the United States; 
by mid-January 2010, estimated vac-
cination coverage among healthcare 
workers was 37.1% (2). Some evi-
dence indicates that willingness of 
healthcare workers to be vaccinated 
with the new vaccine is poor: 48.0% 
in Hong Kong Special Administrative 
Region, People’s Republic of China 
(3) and 22.3% in the United States (4). 
Vaccination coverage was signiﬁ  cant-
ly higher for those 20–30 years of age 
than for those in other age groups (p = 
0.001). The analysis by occupational 
category showed signiﬁ  cantly higher 
coverage for paramedical staff (26%) 
than for physicians and pharmacists 
(19%) (p<0.01). The main causes for 
this reluctance were fear of adverse ef-
fects, concerns about the new adjuvant 
used, the short duration of clinical tri-
als, and inﬂ  uence of the media.
The low acceptance rate of vac-
cination for pandemic (H1N1) 2009 
among healthcare workers in Morocco 
is alarming because they serve as an 
example for their patients and the pub-
lic. Vaccination is needed to keep the 
healthcare system operating at maxi-
mum capacity during a pandemic. 
The following factors appear to play 
a major role in acceptance: accessibil-
ity of the vaccine within the service; 
free vaccine; and a display explaining 
vaccination’s beneﬁ  ts, protective val-
ue, and risk for adverse effects (5,6). 
Policy makers could use our ﬁ  ndings 
to improve the vaccination strategy for 
healthcare workers in future vaccina-
tion campaigns.
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New Rural Focus of 
Plague, Algeria
To the Editor: Plague is a deadly 
rodent-associated  ﬂ  ea-borne  zoono-
sis caused by the bacterium Yersinia 
pestis (1). Human plague periodically 
reemerges in so-called plague foci, as 
illustrated by the 2003 reemergence 
of human plague in the Oran area, Al-
geria (2,3). We report emergence of a 
new plague focus in a remote region 
of Algeria.
In July 2008, three patients came 
to Laghouat University Hospital with 
signs of severe infection and painful, 
inﬂ  amed, enlarged lymph nodes sug-
gestive of buboes. One additional pa-
tient became ill with pneumonia and 
coma after a bubo appeared. The pa-
tients were nomads living in a 24-per-
son camp in Thait El Maa in the Lagh-
ouat area, 550 km southwest of Algiers 
(Figure). Plague was conﬁ  rmed  by 
culturing Y. pestis from 1 bubo aspi-
rate. Ten days of oral doxycycline (4 
mg/kg/d) combined with oral rifampin 
(20 mg/kg/d) and intramuscular gen-
tamicin (3 mg/kg/d) cured the patients 
with bubonic plague, but the patient 
with pneumonic plague died.
In January 2009, eight individu-
als of the rodent species Meriones 
shawii (Shaw’s jird) and 2 Psa-
mommys obesus (fat sand rats) were 
trapped inside nomads’ tents (H.P. 
Sherman Traps, Tallahassee, FL, 
USA). At time of capture, there was 
a cold wind with blowing sand, and, 
after visual inspection of the rodents, 
efforts to recover ﬂ  eas failed. DNA 
from the rodents’ spleens was ex-
tracted by using the QIAamp Tissue 
Kit (QIAGEN, Hilden, Germany) at 
the Medical Entomology Unit Labo-
ratory, Pasteur Institute, Algiers, and 
subjected to PCR ampliﬁ  cation  of 
the plasminogen activator gene (pla) 
from 6 M. shawii jirds. Negative con-
trols (DNA extracted from uninfected 
ﬂ  eas maintained as colonies in Medi-
cal Entomology Unit Laboratory was 
used in the absence of negative ani-
mal tissue) remained negative.
After sequencing, the PCR am-
plicons showed 100% sequence iden-
tity with Y. pestis reference sequences. 
Identiﬁ   cation was further conﬁ  rmed 
in Marseille, France, by culturing 2 
rodent glycerol-negative Y. pestis iso-
lates (Algeria 1 and Algeria 2) and 
sequencing pla, caf, and glpD genes. 
The latter sequence was identical to 
the reference Y. pestis CO92, an Ori-
entalis biotype. Multispacer sequence 
typing found the following combina-
tion: spacer Yp3, type 5; Yp4, 1; Yp5, 
1; Yp7, 8; Yp8, 2; Yp9, 2; and Yp10, 1, 
a pattern that is typical for all Orienta-
lis isolates investigated by this method 
but does not match the combinations 
observed for other genotypes. The 
original spacer Yp7 type 8 ruled out 
contamination (4).
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Figure. Location of a new rural plague focus in a nomad camp in Laghouat (dark gray 
shading; 35°29′N, 0°32′E), Algeria.